Riluzole
NDC Package 0179-0150-70

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

Riluzole is a medication used to treat a certain type of nerve disease called amyotrophic lateral sclerosis (ALS, also commonly called Lou Gehrig's disease). Marketed by Kaiser Foundation Hospitals, this product is identified by NDC 0179-0150 and is authorized under FDA application ANDA091417.

Identification & Billing

NDC Package Code
0179-0150-70
Package Description
30 TABLET, FILM COATED in 1 BOX, UNIT-DOSE
Product Code
0179-0150
11-Digit Billing Format
00179015070

Clinical Specifications

Proprietary Name
Riluzole
Dosage Form
-
Usage Information
This medication is used to treat a certain type of nerve disease called amyotrophic lateral sclerosis (ALS, also commonly called Lou Gehrig's disease). Riluzole helps to slow down the worsening of this disease and prolong survival. However, it is not a cure for ALS, and it does not reverse nerve damage or muscle weakness. Riluzole is thought to work by protecting the nerves in the brain and spinal cord from too much of a natural substance called glutamate that may be part of the cause of nerve damage.

Regulatory & Marketing

Labeler Name
Kaiser Foundation Hospitals
FDA Application #
ANDA091417
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
05-14-2014
End Marketing Date
11-30-2016
Listing Expiration
11-30-2016
Exclude Flag
D
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 0179-0150-70 identifies a specific commercial package of 30 tablet, film coated in 1 box, unit-dose of Riluzole, labeled by Kaiser Foundation Hospitals. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Kaiser Foundation Hospitals on May 14, 2014. The current certification is valid through November 30, 2016.

What are the primary indications for this medication?

This medication is used to treat a certain type of nerve disease called amyotrophic lateral sclerosis (ALS, also commonly called Lou Gehrig's disease). Riluzole helps to slow down the worsening of this disease and prolong survival. However, it is not a cure for ALS, and it does not reverse nerve damage or muscle weakness. Riluzole is thought to work by protecting the nerves in the brain and spinal cord from too much of a natural substance called glutamate that may be part of the cause of nerve damage.

How is this Kaiser Foundation Hospitals product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00179015070. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (4-4-2)
0179-0150-70
11-Digit CMS (5-4-2)
00179-0150-70

Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.